

ANNUAL REPORT



“I support BCRF so no one else has to go through this.”

ALICE JACKSON,
DIAGNOSED IN 2011

A close-up portrait of Alice Jackson, a woman with short, layered brown hair and bangs. She is smiling warmly at the camera, showing her teeth. She is wearing a red top with a white pattern and a pearl necklace. The background is a solid teal color.

2022

BOARD OF DIRECTORS

Leonard A. Lauder,
Honorary Chairman

Kinga Lampert,
Co-chair

William P. Lauder,
Co-chair

Myra J. Biblowit,
President

Deborah Krulewitch,
Secretary

Thomas C. Quick,
Treasurer

Larry Norton, MD,
Founding Scientific Director

Judy E. Garber, MD, MPH,
Scientific Director

Betsy L. Battle

Jerome Bettis

Cindy Citrone

Nina Garcia

Efraim Grinberg

Karen Hale

Susan Hertog

Dee Ocleppo Hilfiger

William S. Karol

Shelly Kivell

Kay Krill

Carlyn McCaffrey, Esq.

Ellen Odoner, Esq.

Abbe Raven

Andrea Redmond

Kendra Scott

Kerone Vatel

Evelyn H. Lauder,
Founder, In Memoriam

Cynthia Lufkin,
Vice Chair, In Memoriam

BCRF SCIENTIFIC ADVISORY BOARD

Larry Norton, MD,
Founding Scientific Director

Judy E. Garber, MD, MPH,
Scientific Director

Vered Stearns, MD,
Chair

Joan S. Brugge, PhD

Sarat Chandarlapaty, MD, PhD

Susan M. Domchek, MD

Patricia A. Ganz, MD

Steffi Oesterreich, PhD

Ben Ho Park, MD, PhD

Martine J. Piccart, MD, PhD

Lori J. Pierce, MD

Lajos Pusztai, MD, D.Phil

Eric P. Winer, MD

SAB Emeritus Members

Nancy E. Davidson, MD

Gabriel N. Hortobagyi, MD

ADVISORY BOARD

Kinga Lampert,
Chair

Arlene Adler

Roberta M. Amon

Louise T. Braver

Andrea Brooks

Ellen Brown

Susan Payson Burke

Elisha Daniels

Iris Dankner

Danielle Do

Kelley Doyle

Suzanne Elson

Claire Florence

Leslie Gifford

Stephanie Ginsberg

Roslyn Goldstein

Lyuba Goltser

Mandy Gonzalez

Marjorie Reed Gordon

Lorna Hyde Graev

Betsy S. Green

Bette-Ann Gwathmey

Lisa Harbert

Ronnie Heyman

Gail Hilson

Susan B. Hirschhorn

Linda Holliday

Wendy Holmes

Jane Hertzmark Hudis

Elizabeth Hurley

Jayne Jamison

Sinesia Karol

Stacie Kiratsous

Lisa Klein

Hope Krakoff

Elyse Lacher

Maralyn Lakin

Laura Lang

Laura Lassman

Eliana Lauder

Heather Leeds

Nancy Mahon

Samira Malik

Kelly Manley

Marisa Acocella Marchetto

Blythe Masters

Mary Bryant McCourt

Gretta Monahan

María Cristina (MC)

González Noguera

Darcy Miller Nussbaum

Mary Alice Pappas

Winifred Gorlin Phillips

Tara Prout

Patricia Quick

Katharine Rayner

Lois Robbins

Wendi Rose

Teruca Rullán

Judith P. Schlager

Nicole Seagriff

Bari Seiden-Young

Liz Kelleher Sells

Pheodora Shin, MD

Jeanne Sorensen Siegel

Anne Sitrick

Joanne Smith

Donna M. Stearns

Arlene Taub

Karen Taub

Jamie Alexander Tisch

Kelley Tuthill

Linda Waintrup

Harriet Weintraub

Candace King Weir

Nina Wexler

Simone Winston



Breast cancer is a complex disease with no simple solution. Every diagnosis is unique and puts lives at risk. We must stop breast cancer in its tracks, and research is the answer.

Founded in 1993 by Evelyn H. Lauder, the Breast Cancer Research Foundation is the largest private funder of breast cancer research in the world. We invest in a wide range of research—prevention, diagnosis, treatment, survivorship, and metastasis—because each area of investigation informs another, propelling us toward the solutions we urgently need.

We convene and connect the best minds in science—giving them the opportunity to pursue their most innovative ideas. Our combination of investment and cross-disciplinary collaboration accelerates the entire field and builds momentum for new discoveries. BCRF-funded investigators have been behind every major breakthrough in breast cancer research, and the field is moving faster than ever. We can't stop now.

With you, and the entire BCRF community, we are fueling the world's most promising research. Join us—together, we will bring the end of breast cancer into focus.

A LETTER FROM LEADERSHIP

With your support, BCRF is fueling the work of 255 investigators in 14 countries and at 87 institutions, collaborating across disciplines and borders. Thanks to you, they're able to take their best ideas from the moment of inspiration to the vanguard of patient care. They break new ground and innovate—all because you help make their research possible.

But this work is far from finished. Breast cancer is now the most commonly diagnosed cancer worldwide. More American women are living with metastatic disease—and there's been a significant rise in later-stage diagnoses among women under 40 years old.

As the world's largest private funder of breast cancer research, and metastatic research, BCRF is uniquely poised to address these sobering realities. We're supporting some of the foremost luminaries and leaders across the globe—scientists who have been behind every major breakthrough in breast cancer research—while simultaneously cultivating the next generation of investigators.

Thanks to you, the researchers we fund are making historic strides and bringing us closer to a future beyond the disease. This year, BCRF-funded investigators reported a groundbreaking new study that revealed the molecular mechanisms driving metastasis—insights that will

potentially uncover new avenues of treatment for some of our most vulnerable patients living with stage IV breast cancer. Simultaneously, our researchers are studying new ways to personalize prevention strategies for individual patients.

To once again foster unprecedented global collaboration and transform the field, BCRF also just launched the world's first data hub for breast cancer, providing researchers with a one-stop shop to access and analyze critical information to support and spark new inquiries.

These advances and others offer real reasons for hope—and renewed determination.

Led by the vision of a deeply motivated Board of Directors comprised of trailblazers in business, finance, law, media, and philanthropy, BCRF—and our community of renowned researchers—is moving research forward, faster.

We're grateful for every gain we've made against breast cancer, and for every additional day those breakthroughs give us with those we love. Thank you for all you do to accelerate the pace of research. It's only through this progress that we can hope to save more lives.

With our deepest gratitude,



Myra J. Biblowit
President & CEO



Kinga Lampert
Co-chair



William P. Lauder
Co-chair

BCRF LAUNCHES GLOBAL DATA HUB FOR BREAST CANCER RESEARCH

In October 2022, the BCRF launched its Global Data Hub, a first-of-its-kind, centralized collection of breast cancer research data that will dramatically expedite new studies and amplify the impact of all BCRF investments.

No single data point, or even database, will be the end of breast cancer. The power of data is in the aggregate—when results from several genetic, molecular, and clinical studies are combined to make scientific conclusions. Big data takes this one step further: By amassing large datasets and coupling them with artificial intelligence, researchers can pursue ideas they never could have explored in isolation.

Yet, research often yields mountains of data that are underutilized, and discoveries are hiding in this untapped information. As a visionary leader in breast cancer research, BCRF stands to revolutionize the field once again.

In the current research environment, scientists access breast cancer data by navigating disparate databases. Genetic tests, tissue biobanks, electronic health records, and molecular data are all spread across multiple sites. Many datasets are difficult to find, and those that are accessible are not breast cancer-specific.

BCRF is uniquely poised to launch the first Global Data Hub dedicated to breast cancer research. The Foundation's unparalleled global network of leading researchers, deep experience coordinating international research consortia, and existing partnership with the University of Pittsburgh—a leader in supercomputing—is the ideal collection of expertise to build this centralized hub. This modern, cloud-based research portal will facilitate “one-stop shopping” for laboratory- and patient-derived data in the field.

“Data sharing and interconnectivity are desperately needed in research, and the BCRF Global Data Hub will, for the first time, provide the infrastructure and community to make it happen in the field of breast cancer,” said BCRF Chief Scientific Officer Dorraya El-Ashry, PhD. “We aren't just propelling research forward—we're paving a new future for science.”

BCRF'S APPROACH TO COLLABORATION AND INNOVATION IN DATA SHARING

The BCRF Global Data Hub will include all relevant BCRF-supported datasets from its investigators around the world, and this integration will begin this year. In the outyears, data will be invited from and made available to the wider breast cancer community to ultimately impact all breast cancer research.

“Our tiered approach to launch will ensure sustainable growth of the Hub,” said BCRF Scientific Director Judy Garber, MD, of Dana-Farber Cancer Institute. “When access further extends to all breast cancer researchers, the possibilities will be endless.”

One of BCRF's biggest datasets to date is the world's largest repository of matched primary and metastatic tumor data, collected by the AURORA projects to illuminate the metastatic process. Based in Europe and the U.S., AURORA is supported by BCRF's Evelyn H. Lauder Founder's Fund for Metastatic Breast Cancer Research. Ensuring that the world's leading minds in breast cancer have access to this data, through the Global Data Hub, will be vital to advancing our understanding of metastasis.

A READY-MADE PARTNERSHIP: BCRF AND THE UNIVERSITY OF PITTSBURGH

The computing power behind the BCRF Global Data Hub lies with Chief Research Informatics Officer Jonathan Silverstein, MD, and his team at the Pitt School of Medicine. This team will design and manage the Hub's overall technical approach and coordinate data security to ensure the highest regulatory and data privacy standards.

“Looking at the heavenly bodies in the night sky all the ancients could do was wonder. Modern astronomy started with that wonder, but it was the collection of massive amounts of data and its organization in libraries that allowed the great scientists of yesteryear to solve the mysteries of physics,” said BCRF Founding Scientific Director Larry Norton, MD, of Memorial Sloan Kettering Cancer Center. “We are now embarking on a similar journey, gathering biologic data, and making it usable to the great scientists of today so that we may, finally, solve the mysteries of cancer.”



OUR APPROACH

BCRF is built on the belief that research is the only means to end breast cancer. However, research conducted in academic or industrial silos hampers progress and slows our trajectory. That’s why BCRF bridges the gap between the foremost scientists—across institutions, across disciplines, and across the globe.

BCRF’s Scientific Advisory Board (SAB), comprised of the world’s preeminent breast cancer experts, directs our research efforts by seeking the promise and potential in individuals who can help us end breast cancer.

Each year, BCRF’s scientific advisors invite proposals from pioneering laboratory scientists and clinical investigators making headway in cancer research. After careful deliberation and an assessment of the most promising leads, the SAB awards grants once a year. Our support enables scientists to use their creativity and ingenuity, unfettered, to explore their most innovative scientific ideas.

BCRF also supports consortia, clinical trials and large initiatives to address specific areas of breast cancer research such as prevention and metastasis. Through partnerships with other major scientific organizations, BCRF supports the next generation of promising young investigators with early- and mid-career grants.

This unique grant model creates a collaborative space that fosters the free exchange of ideas and sharing of data between scientists hailing from a wide range of disciplines. Scientists from specialties including artificial intelligence, biology, engineering, chemistry, nursing, machine learning, mathematics, surgery, and many others work together to propel research forward, faster.

BCRF-funded researchers have been involved in every major breakthrough in breast cancer prevention, diagnosis, treatment, survivorship, and metastasis.

SCIENTIFIC ADVISORY BOARD

Founding Scientific Director
Larry Norton, MD
Memorial Sloan Kettering Cancer Center

Scientific Director
Judy E. Garber, MD, MPH
*Dana-Farber Cancer Institute
Harvard Medical School*

Chair
Vered Stearns, MD
Johns Hopkins School of Medicine

Joan S. Brugge, PhD
Harvard Medical School

Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center

Susan M. Domchek, MD
University of Pennsylvania

Patricia A. Ganz, MD
University of California, Los Angeles

Steffi Oesterreich, PhD
University of Pittsburgh

Ben Ho Park, MD, PhD
Vanderbilt University Medical Center

Martine J. Piccart, MD, PhD
Institut Jules Bordet

Lori J. Pierce, MD
University of Michigan

Lajos Pusztai, MD, D.Phil
Yale School of Medicine

Eric P. Winer, MD
Yale School of Medicine

SAB Emeritus Members
Nancy E. Davidson, MD
Gabriel N. Hortobagyi, MD

OUR GROWTH



BCRF researchers are attacking cancer from all angles. Each area of focus will ultimately inform important goals including stopping breast cancer from spreading (metastasis) and stopping breast cancer from happening altogether (prevention).

To best achieve these goals, we must support the entire spectrum of research—from basic science studying the very roots of the disease, to clinical trials moving precision treatments from the lab to the bedside.



Lifestyle and Prevention

Developing strategies to intervene on cancer risk factors and to reduce risk.



Heredity and Ethnicity

Understanding the genetic causes of breast cancer and how race and ethnicity play a role to better stratify patient risk.



Tumor Biology

Understanding the evolution from normal cell to cancer cell and how the tumor microenvironment supports or suppresses its growth.



Treatment

Developing and testing precision treatments.






Metastasis

Understanding how tumors spread to and grow in different organs.



Survivorship

Enhancing quality of life, cancer control, and improving health outcomes.

	1993-94	2022-23
 \$ IN RESEARCH	\$160K	\$52.7M
 COUNTRIES	1	14
 RESEARCHERS	8	255

 NEW TREATMENTS

OUTSMARTING CANCER

While we have seen significant progress developing new treatments for breast cancer over the last few decades, much work remains. We urgently need more treatments for people diagnosed with advanced and aggressive breast cancers, as well as early-stage (stage 0-1) breast cancers that are resistant to currently available drugs. BCRF is taking on these challenges by advancing precision medicine.

There are many types of breast cancer with unique characteristics that respond differently to treatments. The most common type of breast cancer is invasive ductal carcinoma, which can be further classified into several subcategories including:

HORMONE SENSITIVE (ER+) BREAST CANCER

Breast cancers driven by the hormone estrogen (ER-positive) typically respond well to drugs that block estrogen production or activity. Several anti-estrogen drugs, including tamoxifen, are available. Thanks to BCRF investigators, new targeted drugs have been approved for advanced ER-positive breast cancer including CDK4/6 inhibitors, mTOR inhibitors, and an oral selective estrogen degrader.

HER2+ BREAST CANCER

Breast cancers driven by the HER2 protein are typically fast growing and were very difficult to treat until a drug called Herceptin® was approved by the FDA in 1998—thanks in part to BCRF-funded investigators who demonstrated the drug’s efficacy through rigorous clinical trials. BCRF investigators were also involved in testing the first anti-HER2 drug for treating patients with brain metastases, leading the FDA to approve the therapy in 2020. More recently, researchers showed that low levels of HER2 could be targeted with a type of drug called an antibody-drug conjugate—a major advance that stands to give up to 75 percent of breast cancer patients a new treatment option.

TRIPLE-NEGATIVE BREAST CANCER

Triple-negative breast cancer (TNBC) is a type of breast cancer that is characterized by its lack of expression of

estrogen or progesterone receptors and HER2 protein (hence the term triple-negative). This form tends to be more aggressive and is harder to treat. TNBC disproportionately impacts younger women, Black women, and BRCA mutation carriers.

BCRF PORTFOLIO

EXPANDING TREATMENT OPTIONS FOR TNBC

While there are few targeted therapies for TNBC, BCRF funded studies have provided important insights. The identification of TNBC subtypes, for instance, is helping to identify targeted therapies, such as immunotherapy, PARP inhibitors, and anti-androgen drugs, for patients with this form. BCRF is investing nearly \$13 million in TNBC research.

REDUCING DRUG RESISTANCE

BCRF is investing more than \$8.9 million in research aimed at understanding how tumor cells become resistant to drugs designed to kill them and how to prevent it. Researchers are working to discover new targets that drive drug resistance, novel combinations to prevent resistance, and biomarkers to identify patients not likely to benefit from a specific drug.

IMMUNOTHERAPY

Immunotherapy involves harnessing the power of a person’s own immune system to attack their cancer. Many experts believe that immunotherapy may play an important role in combination with standard therapies such as radiation, chemotherapy or other immunotherapy drugs. BCRF is investing over \$10 million this year into studies on breast cancer and immunotherapies.

TREATMENT OPTIMIZATION

Biomarkers are key to achieving the primary goal of precision medicine: giving the right drug to the right person at the right time. BCRF is investing over \$21 million in studies to both identify and validate biomarkers to provide the right drug for each patient.


IN 2022-2023 BCRF IS INVESTING



Nearly **\$30 million** in treatment research



funding **138** projects



“TNBC tends to be diagnosed in younger people. Many of these people are mothers raising children, having a family. We need to better understand this disease.”

—KATE
DIAGNOSED IN 2019



LIFESTYLE AND PREVENTION

REDUCING RISK

Most breast cancers are not caused by known inherited gene mutations and most people diagnosed with breast cancer do not report having a family history of the disease. While the underlying causes of breast cancer are not entirely understood, studies suggest that at least half of cancer cases can be prevented through lifestyle choices and risk-reduction strategies.

BCRF PORTFOLIO

The same recommendations for preventing heart disease, hypertension, and diabetes may also reduce one's risk of breast cancer. Even someone with a higher-than-average breast cancer risk due to family history may lower their overall risk with preventive strategies. BCRF-funded research has shown that weight loss at any age significantly lowers breast cancer-associated biomarkers in the blood. Researchers are working to understand how lifestyle interventions including diet and exercise regimens impact breast cancer risk from adolescence into adulthood.

BCRF's Precision Prevention Initiative aims to replicate the tremendous gains made in precision medicine—improving treatment and reducing the number of breast cancer deaths—for prevention research. Currently funded projects range from identifying high-risk individuals by harnessing the tools of artificial intelligence to finding new targets for chemoprevention. These projects are critical to our goal of stopping cancer before it starts.

IDENTIFYING HIGH-RISK INDIVIDUALS

Mutations in breast cancer susceptibility genes, like BRCA1 and BRCA2, dramatically increase the lifetime risk of breast and other cancers in families. In 2020, a groundbreaking BCRF-funded study identified key breast cancer susceptibility genes in women with no family history. Identifying high-risk individuals before cancers develop is key to prevention. BCRF investigators are testing strategies to increase genetic testing and counseling, and investing more than \$9 million to understand hereditary breast cancer.

REDUCING THE RISK OF RECURRENCE

When diagnosed early, most breast cancers can be treated successfully. The five-year survival rate for early-stage breast cancer (stage 0-1) is nearly 100 percent. Recurrences, including those that occur 10, 15, and 20 years after initial diagnosis and treatment, remain a serious clinical concern. Treatment with anti-estrogen therapies can dramatically reduce a person's risk of recurrence.

Understanding which groups are at highest risk and ensuring access to screening and appropriate genetic counseling are key prevention strategies in this population.



IN 2022-2023 BCRF IS INVESTING



More than **\$7 million** in lifestyle & prevention research



funding **40** projects



*“I’m a fighter.
I went through
some hardships
in my life, and
this was the
toughest thing
I have done.”*

—ANDRE
DIAGNOSED IN 2021



HEREDITY AND ETHNICITY

UNDERSTANDING RISK FACTORS

Many risk factors influence whether a person will develop breast cancer, including family history, gender, age, race, and ethnicity. Cancer risk is also influenced by lifestyle, reproductive history, environment, and other markers.

BCRF PORTFOLIO

BCRF-funded researchers are advancing our understanding of inherited gene mutations, developing low-cost genetic testing, finding targeted treatments for breast cancers caused by these genetic factors, and studying the impact of race on breast cancer occurrence and outcomes.

INHERITED RISK: SCREENING AND PREVENTION

Up to 10 to 15 percent of breast cancers are thought to be due to hereditary factors. The most prominent of these are the mutations in BRCA1 and BRCA2 genes passed down in families. Mutations in BRCA1 and BRCA2 significantly increase the risk of breast and ovarian cancer, as well as a number of other cancers. BRCA mutations, however, account for only five to 10 percent of hereditary breast cancers. Other confirmed breast cancer-predisposing genes include PALB2, CHK2, BARD1, TP53, ATM, and many more for those with and without a family history. Research is also revealing the potent interplay of mutations—those that may not pose a danger individually but when in combination with others may increase risk significantly. Thanks to these discoveries and genetic testing, high-risk individuals can be identified before cancer starts and are able to undertake preventive measures to reduce their risk of breast cancer.

RACE AND ETHNICITY

Inherited risk can come from genetic factors passed down in families but can also be influenced by race and ethnicity.

Work by BCRF investigators leads the way in advancing our understanding of breast cancer in Ashkenazi Jewish, Arab, African, African American, Indian, and Latin American populations.

While BRCA mutations are rare in the general population, certain populations have a much higher risk of inheriting a BRCA mutation. In Jewish people of Ashkenazi (Eastern European) descent, the chance of inheriting a BRCA gene mutation is 1 in 40, compared to 1 in 400 in the general population. BRCA mutations account for up to 10 percent of breast cancer and 40 percent of ovarian cancer cases in Ashkenazi Jews. Researchers are also studying the frequency of BRCA1 and BRCA2 mutations in Palestinian Arabs and non-Ashkenazi Jewish populations in Israel and the Middle East. Thanks to BCRF, genetic testing is now routinely performed for breast cancer patients at most major Palestinian hospitals.

BCRF investigators are studying DNA differences associated with race to increase our understanding of breast cancer biology, particularly for more aggressive triple-negative breast cancers, which occur more frequently in young women, and young Black women in particular. BCRF investigators were the first to discover that Black and Hispanic women have a higher incidence of mutations in BRCA1 and BRCA2, as well as other inherited susceptibility genes, than their white counterparts. Of all the ways we can help eliminate health care disparities, facilitating and accomplishing innovative research is one of the most far-reaching.

IN 2022-2023 BCRF IS INVESTING



More than **\$9 million** in heredity & ethnicity research



funding **49** projects

A portrait of a Black woman with her hair pulled back, wearing a blue top and several necklaces. She is looking slightly to the right of the camera with a gentle smile. The background is a light, neutral color.

“Black women
tend to have more
aggressive cancer
and be diagnosed
at younger ages.
We need research.
We need more
research.”

—TRACEY
DIAGNOSED IN 2014



TUMOR BIOLOGY

UNCOVERING CANCER'S ROOTS

Tumor biology is integral to nearly every new discovery that will lead to advances in clinical care. The completion of the Human Genome Project in 2003 dramatically altered how we study tumor biology. Discoveries that uncovered how cancer can be driven by gene mutations and environmental interactions provided new insights and deepened our understanding of the disease and its treatment. Adding to the complexity of the human genome, we are now learning how the proteome (the protein profile), metabolome (metabolite profile), and even the microbiome (microorganisms that are a natural part of our human biology) influence cancer growth and outcomes.

And yet, laboratory research is not linear in progress. It takes years for research to result in changes in clinical practice that improve patient outcomes. Discoveries made at the laboratory bench guide drug development and clinical trials. Results from clinical trials subsequently guide laboratory research in a cycle of intellectual feedback and iterative progress. We are committed to accelerating this process and delivering new discoveries to patients in the shortest time possible.

BCRF PORTFOLIO

Research that is unraveling in tumor biology—the initiation of cancer, its progression, the interaction with its micro and macroenvironment, and metastasis—comprises the core of BCRF's research portfolio. These studies may be laboratory-based or discovery research but are more often translational with a focus on rapidly moving discoveries made in the laboratory into clinical application.

Discovery-based research studies range from single-cell analyses of alterations in tumor genes and proteins to the complex inter-relationships of tumor cells and normal cells around them that influence tumor cell behavior (the tumor microenvironment).

BCRF investigators employ sophisticated state-of-the-art technologies, many developed with BCRF support, to model human breast cancer under laboratory conditions. Cancer cells are visualized in real time, tumor cell behavior is studied in response to drugs or other stimuli, and molecular targets are identified for new therapeutics. These targets are then validated in human breast cancer tissue to confirm that they are in fact important in tumor growth and viable targets.

Within the vast field of tumor biology, there are a few key areas of focus. The study of breast cancer stem cells is critical because they are believed to be essential to tumor development, drug resistance, and metastasis. The field of tumor heterogeneity examines the complex diversity of cells within a single tumor. Additionally, studies of the tumor microenvironment reveal how the microscopic world surrounding tumor cells, in particular cells of the immune system, may allow them to grow or spread.

Understanding the basic biology of breast cancer allows us to get to the very core of the disease. Every aspect, from a cancer cell's genes to the tumor's environment, is under investigation. BCRF investigators are giving us the knowledge to achieve prevention and develop new treatments and cures.

IN 2022-2023 BCRF
IS INVESTING



Nearly **\$33 million**
in tumor biology research



funding **149** projects



SURVIVORSHIP

IMPROVING QUALITY OF LIFE



Advances in early detection and treatment have largely contributed to a decline in deaths due to breast cancer over the past three decades, creating the largest cancer survivorship cohort in the history of the United States. According to the American Cancer Society, there are an estimated 4 million people in the U.S. living with a history of breast cancer. Of those, an estimated 168,000 women and men are living with metastatic breast cancer and receiving ongoing treatment.

Life after breast cancer (a period often referred to as survivorship) is a unique experience for each individual and is influenced by many factors including age, socioeconomic status, geographic location (urban vs. rural), family and social support networks, health insurance, and others.

The goal of breast cancer treatment is to extend patients' lives, but those lifesaving treatments can have persistent physical and emotional effects. Treatment-induced symptoms such as peripheral neuropathy (pain or numbness in the fingers or feet), lymphedema (build-up of lymph fluid under the skin causing uncomfortable swelling in the arms and hands), sexual dysfunction (such as vaginal dryness and loss of libido), and cognitive impairment (sometimes called chemo brain) can persist long after the treatment has ended. Because women are living longer

after breast cancer treatment, managing long-term side effects of treatment is important to patients' quality of life during those extended years. Those with metastatic breast cancer face the persistent challenges of these physical and emotional effects.

BCRF PORTFOLIO

With BCRF support, researchers are working to personalize care and better predict and manage side effects, to not only increase lifespan with more effective therapies, but improve the quality of life for patients during and after treatment.

BCRF-funded studies include projects specifically aimed at issues facing young women with breast cancer, such as improving or maintaining sexual health during and after treatment. Projects are also aimed at developing tools to ease disease monitoring and identify patients most likely to experience toxic side effects, while another is developing interventions to reduce stress and improve self-confidence, self-esteem, and overall well-being in women with breast cancer. In addition to other quality of life studies that benefit patients at any stage of breast cancer, BCRF is supporting research to address issues of stress and depression for patients with metastatic breast cancer.

IN 2022-2023 BCRF
IS INVESTING



More than **\$6 million**
in survivorship research



funding **33** projects



METASTATIC BREAST CANCER

HOW CANCER SPREADS

Metastatic breast cancer occurs when breast cancer cells spread to other parts of the body, including vital organs such as the lungs, liver, brain, or bones. Metastatic breast cancer, also referred to as stage IV, is incurable and responsible for virtually all breast cancer-related deaths—about 44,000 each year. As of the most recent data, from 2020, there are an estimated 168,000 women and men living with metastatic breast cancer in the U.S.

BCRF PORTFOLIO

BCRF investigators are studying every aspect of metastatic breast cancer—from understanding how cancer cells invade and spread, to testing new treatments in clinical trials. Progress is being realized: In the last seven years, ten drugs for metastatic breast cancer have been approved. While we’ve made significant strides, we still have much to learn about this form of the disease.

In 2022-2023, BCRF is committing 41 percent of our grant-making program to metastasis research. Projects include those seeking to: understand the intricacies of the events that lead to cancer cell invasion into local tissue; identify new markers to predict one’s risk of metastasis and new targets for drug development; and test novel treatments in clinical trials.

AURORA US and EU, the flagship programs of BCRF’s Evelyn H. Lauder Founder’s Fund for Metastatic Breast Cancer Research, recently achieved new milestones.

In the last year, investigators from these complimentary studies published several notable findings. Among them, researchers identified significant differences in molecular subtype, genomic landscape, and the immune microenvironment in metastatic tumors compared to primary tumors from the same patients. Understanding these differences is vital to prevent, detect, and treat metastases more efficiently. Both AURORA EU and US will provide valuable insights to better identify patients at risk of metastasis before it occurs, or much earlier, and to help develop new, more effective therapies or improve response to existing options.

Collectively these complimentary studies are unprecedented in both scale and scope, steering us toward a path of not only better understanding metastasis, but identifying therapeutic targets specifically in metastatic breast cancer—the ripple effects of which may benefit all cancers.

**IN 2022-2023
BCRF IS
INVESTING**



More than
\$21.6 million
in metastatic breast
cancer research



funding
84 projects



comprising
more than
41% of BCRF’s
overall grant
program

BCRF is the largest private funder of metastatic breast cancer research in the world.



“I believe there
are many
ways to get to
optimal health.
Only through
research will
we find
a cure.”

—**SUSIE LEE**
LIVING WITH
METASTATIC BREAST
CANCER

SUPPORT FROM COAST TO COAST



PHOTOS: #1: Dr. Judy Garber and Roslyn Goldstein
 #2: Linda Holliday, Kelley Doyle, Hope Krakoff, Simone Winston, Sinesia Karol, and Elisha Daniels, #3: Elizabeth Hurley, William P. Lauder, Myra Biblowit, and Kinga Lampert #4: Ian Ginsberg, Stephanie Ginsberg, Alec Ginsberg, and Reed Ginsberg, #5: Rob Hale, Helder Cunha, Zach Schellhaas, Laura Michaud, and Nate Michaud, #6: Drs. Larry Norton, Melinda Irwin, and Hayley McDaid, #7: Cindy Citrone, Gabriela Citrone, and Rob Citrone, #8: Barbara Tober



PHOTOS: #1: Play for P.I.N.K. Millbrook Luncheon
#2: Arlene Taub and Michelle Tesser

EVENTS & COMMUNITIES

BCRF's founding in 1993 changed the trajectory of breast cancer—and cancer as a whole. The field is moving faster than ever, and we are leading the charge. Our investigators have been behind every major breakthrough in breast cancer research for nearly three decades. BCRF's vital—absolutely lifesaving—work simply would not happen without the generosity of our supporters.

Our dedicated donors and volunteer leaders from communities across the country are continually finding new and innovative ways to raise funds for research. Our supporters are fueling the world's most promising research by participating in BCRF's signature and regional events, organizing independent fundraisers, and working with dedicated partner organizations. Only with their continued support can we hope to not just sustain, but increase our momentum, without losing ground on decades of research progress.

BCRF's signature, regional, and independent events raised over \$17 million in 2021-2022, fully funding 77 research grants. Donors worked creatively and strategically to expand BCRF's reach in Boston, Long Island, New York City, Palm Beach, Westchester, and Los Angeles. From running marathons to taking Facebook fitness challenges, BCRF's dedicated independent fundraisers mobilized their communities, across nearly all 50 states, to support our mission.

Longtime partner **Play for P.I.N.K. (PFP)**, a volunteer-driven organization of which BCRF is the sole beneficiary, once again successfully harnessed the power of volunteers across the country. In 2021-2022, over 30,000 participants nationwide supported PFP through various sporting and lifestyle events raising \$5 million for research. PFP is underwritten with support from its Title Sponsor, The Estée Lauder Companies' Breast Cancer Campaign, allowing 100 percent of PFP funds raised to support research.

In 2021-2022, the **Women's Cancer Research Fund (WCRF)**, a program of BCRF, raised nearly \$300,000 for grants across the spectrum of cancer research. This year, WCRF is supporting the work of two BCRF investigators pioneering liquid biopsy for breast cancer.

The Pink Agenda (TPA) is a young professionals organization dedicated to raising awareness and funding breast cancer research in partnership with BCRF. Last year, TPA's millennial donor base raised nearly \$1 million for research through events and campaigns in New York, Atlanta, Boston, Chicago, and D.C. In collaboration with Giuliana Rancic's FAB-U-WISH initiative, TPA also granted nearly 50 memorable wishes to women who were undergoing or had recently completed treatment for the disease.



CORPORATE PARTNERSHIPS

IN 2021-2022

Our partners are driving critical funding for research and making a tangible impact. The cumulative impact spurred by our corporate partners is fueling nearly 550,000 hours of research around the globe. Each year, invaluable collaboration across the private sector propels us toward more effective treatments, new prevention strategies, and ultimately, an end to breast cancer. By rallying far-reaching communities, our brand partners harness their global,

collective power to fund lifesaving breast cancer research. BCRF works hand-in-hand alongside each one of our valued partners to mobilize communities for good. BCRF's corporate partnerships program is considered the gold standard in cause marketing and partnerships by the the New York State Attorney General's Office. Together, BCRF and our partners are creating meaningful impact through brands, supporters, and the communities they reach.

NUMBER OF RESEARCH
HOURS FUNDED:
NEARLY
550,000

PARTNERS FUNDED
RESEARCH ACROSS
**15 STATES AND
9 COUNTRIES**

NUMBER OF **PARTNERS**:
120+

PARTNERS RAISED:
\$27.4
MILLION

THE POWER OF PHILANTHROPY



THANKS TO YOU

We know more about the origins of cancer than ever before.
One-size-fits-all treatment is a thing of the past.
Fewer patients with low-risk cancer are overtreated.

We are grateful to all of our donors for their generous support during the year that ended June 30, 2022.

The following donors are supporting research projects around the world with gifts of \$250,000 or more.

\$4,000,000 OR MORE

The Estée Lauder Companies
Play for P.I.N.K.®
Simons Foundation International
Ulta Beauty

\$2,000,000 - \$3,999,999

Ann Taylor and LOFT
Bloomberg Philanthropies
Delta Air Lines
Marilyn and Jim Simons

\$1,000,000 - \$1,999,999

AutoNation, Inc.
The Estée Lauder Companies
Charitable Foundation
Karen and Rob Hale
Jerry and Terri Kohl/Brighton
Collectibles, Inc.
The Lampert Foundation
Leonard & Judy Lauder Fund
William P. Lauder and
Lori Kanter Tritsch
Macy's, Inc.
Estate of Margaret Leigh Pate
The Pink Agenda®
The von Mandl Family Foundation

\$500,000 - \$999,999

Jackie and Mike Bezos
Bloomingdale's, Inc.
David Yurman
Joseph and Arlene Taub Foundation

\$250,000 - \$499,999

Jody and John Arnhold
Beth Park-Field Revocable Trust
Tatiana and Peter Cancro
Cure in Our Lifetime
Cytiva
Friends and Family of Jen and
Josh Feinberg
Genentech, Inc.
Roslyn and Leslie Goldstein
Neil Golub
Gray Foundation
Roger and Susan Hertog
Kendra Scott
Lane Bryant
Evelyn H. Lauder CLAT
Lifetime
Tanger Factory Outlets
Zeta Tau Alpha

SUPPORT FROM COAST TO COAST

\$100,000 - \$249,999

Asmodee North America
Belk, Inc.
Owen W. and Anne P. Blum Charitable
Remainder Trust
Clarissa and Edgar Bronfman, Jr.
Cedar's Mediterranean Foods, Inc.
CertaPro Painters, Ltd.
Citrone 33
Conair Corporation
Estate of Theodore M. Corbo
Frederick Crowley
D'Arrigo California
Firmenich
fuboTV, Media Inc.
Amy P. Goldman Foundation
The Horace W. Goldsmith Foundation
Friends and Family of Samantha
Griffith-Shoobs
Hearst
Housewares Charity Foundation
Humble Bundle, Inc.
Sinesia and Bill Karol
Michele and Howard Kessler
Lids
Lilly Oncology
Lufkin Family Foundation
Samuel I. Newhouse Foundation
Mary M. O'Hern
Pall Corporation
PANDA Entertainment, LLC
Estate of Maxie Parker
Pfizer, Inc.
Pink Boat Regatta
Thomas C. Quick
Jeanne Sorensen Siegel and Herbert J. Siegel
Kate Capshaw and Steven Spielberg
Texas Roadhouse Holdings, LLC
TFT Wheeling/Chantelle Kern
Lizzie and Jonathan Tisch
Traders4ACause
Candace King Weir

\$50,000 - \$99,999

Madelyn Bucksbaum Adamson
Darla and Craig Albert
Almira Family Foundation
Apollo Tools, Ltd.
Armaly® Brands
AstraZeneca
Clay Barr
Betsy L. Battle
Rita and Charles Bronfman
Andrea Brooks
Bunco for Breast Cancer
Capcom Co., Ltd.
Linda and Tom Coates

Chris and Misha Collinson
Color Street Foundation, Inc.
Creating Healthier Communities
Cuisinart
Daiichi Sankyo Cancer Enterprise
Delta Sonic Car Wash Systems, Inc.
Eisai Inc.
For The Girls, Inc.
Amy and Brian France
Mary-Ann and Fabrizio Freda
Funko
Nina Garcia and David Conrod
GHOST
GNC Holdings, LLC
Lilli Gordon
Gorjana & Griffin, Inc.
Mr. and Mrs. Efraim Grinberg
Dee and Tommy Hilfiger
Steve and Bonnie Holmes
June and Rochelle Jacobs
Jimmy Choo
Elton John Charitable Fund
The Kors Le Pere Foundation
Kay Krill
Deborah and Peter Krulewitch
The Patricia E. Laca Trust
Lands' End
Lilly Pulitzer
Lisa F. Levin
Mr. and Mrs. Lawrence Mandel,
Key Food Stores Co-op Inc.
The McCance Foundation
Medical Research Charities
Microflex Corporation
Movado Group
NAKEDCASHMERE
New England Patriots Foundation
Novartis
NutriBullet
Papyrus-Recycled Greetings, Inc.
Patricia Quick
Radar Tires (Omni United)
Abbe Raven and Martin Tackel
Andrea Redmond
Estate of Arthur M. Rigg
John Rosenwald
Brett Saarela and Eric Miller
Sabika Jewelry
Lily Safra
Sanofi-Aventis
Sezane
Laura and Harry Slatkin
The Smidt Foundation
Fred B. Snite Foundation
Donna and James Stearns
Tatum Ranch Golf Club
Taylor Family Foundation

Jamie Alexander Tisch
Tish and Snooky's Manic Panic® NYC
Vionic Group LLC
The Wasily Family Foundation
The Mark and Joanne Webb
Philanthropic Fund
Cynthia C. Weiler and E. Blake Moore, Jr.
for Team Caroline
Nina and Gary Wexler
Lois Robbins and Andrew Zaro

\$25,000 - \$49,999

7M Ranch Fund
A.T. Kearney (International) AG
Acquavella Family Foundation
Augustine Agrizzo Trust
AHB Foundation
Alaska Run for Women
Americans For the Cure of Breast Cancer
Roberta M. Amon
Susan and Richard Anderson
Geoffrey A. Ballotti
Charlene Barshefsky
The Eleanor Collins Boas Foundation
Estate of Jeannine Bouillier Siegmond
Susan and Jonathan Bram
Brandon's Bourbon, Inc.
Louise T. Braver
Laura Louise Breyer
The Bromberg Group at Morgan Stanley
The Buller Foundation
C.O. Bigelow Apothecaries/Stephanie
and Ian Ginsberg
Eleanor S. Campbell-Swank
Capacity Studios
Shelley and Michael Carr
Castiglione Charitable Trust
Charleston's-Omaha, Inc.
Colgate-Palmolive
Conquer Cancer®, the ASCO Foundation
D. Clegg Construction, Inc.
Dapper Dinos
Danielle Do and Sam Sutton
John Donnelly
Dream Makers of GFWC-SC
Fashion Strikes Cancer
Cyndy and John Fish
Scott Fishman
Florida Crystals
Carol J. Fox
Lisa and Tomas Friedlander
Fuente Family Foundation
Givaudan
Griffith Family Charitable Foundation
Agnes Gund
Jean Helfenstein and Iva Ilieva
The Hess Foundation

Ronnie F. Heyman
Holiday House
Linda and Jay Hooley
Imagine Dance Challenge
Alice and Mike Jackson
JPMorgan Chase & Co.
Nancy and Rick Kelleher
Stacie Kiratsous
Shelly and Howard Kivell
Koi Design, LLC
Jonathan and Patricia Kraft
Hope Krakoff
Elyse Lacher
LAGOS
Lambert Family Foundation
Jo Carole and Ronald S. Lauder
Laura and Gary Lauder
Leechburg's Pink Day
Wayne Liu (Perfect Corp)
Lowenstein Sandler LLP
The Lynch Foundation
John and Linda MacDonald Foundation
James R. Malek
Carlyn S. McCaffrey, Esq.
Medaptive Health
The Estate of Evelyn Meisner
Memorial Sloan Kettering Cancer Center
Roberta and Joseph Menzin
MI Charitable Foundation
Estate of Marilyn C. Miller
"Miranda Fund" of the Community
Foundation of New Jersey
Mizuno USA, Inc.
The Ambrose Monell Foundation
Hugh M. Neil 2018 Revocable Trust
Amy E. Newburger, MD
Omnicom Media Group
Margaret and Andrew Paul
Peloton
PGAL
Kathryn Pinch
Pink Lemonade Stand Challenge
Pinkathon San Francisco
Carol and Luke Praxmarer
Pronovias USA, Inc.
The Rallis Foundation
The Ralph Lauren Corporate Foundation
RatPac Controls
Wendi Rose/Marshall Rose Family Foundation
Saks Fifth Avenue
Joy Sargent
George A. Schilling
Kim and Mac Schuessler
Richard and Suzanne Schultz
Marc Schwartz in memory of Bonnie Schwartz
SCIEEX LLC
Carl & Ruth Shapiro Family Foundation

Drs. Myung and Pheodora Shin and Family
Sipher
SmartStop Asset Management
Barbara and Randall Smith
Cheryl and Lonnie Smith
Ronald J. Spector
Joseph F. Stein Family Foundation, Inc.
Judy and Michael Steinhardt
Stephanie Gottlieb, LLC
The Barry S. Sternlicht Foundation
Tail Activewear
ThirdLove
TIEM Athletic
Barbara Tober
UBS
Union Beverage Packers, LLC
Estate of Betty Ann Utterback
WCN Group
We Evolve Together, LLC
Lisa Wolman
Woodstock Bunco for Breast Cancer
Wyndham Hotels & Resorts

\$15,000 - \$24,999

Alley Katz, Inc.
AmazonSmile
Madeline and Stephen Anbinder
AppDynamics/Cisco Systems
Kaye Arnold
Arthrex, Inc.
Athletic Propulsion Labs, LLC
Steven Barnholtz
Baron Capital Management Inc.
Joan and Robert Blackman
BNY Mellon
Cynthia Breen and Laurie Dowley
Brigham and Women's Hospital
Ellen and Michael Brown
Richard Calder
Patsy and Patrick Callahan
Carol and Richard Chadakoff
Laurent Claquin
Community Health Center, Inc.
Convergint Technologies
Crescent Electric Supply Company
Cross Country Healthcare
Pamela and Charles Crum
Custom Ink, LLC
Dana-Farber Cancer Institute
Danaher Foundation
Diamond Products Limited
Dickinson + Associates
Joshua Dixon
The Dozen Dimes Foundation
Dress Up Buttercup
Lois J. and L. David Dwyer
EC Design, LLC

Edge Fitness, LLC
Empire BlueCross BlueShield
Andrew L. Farkas, Island Capital Group
& C-III Capital Partners
Allison and Larry Fehrenbaker
Tiffany Formsma
Paul Fribourg/Continental Grain Company
The Gabelli Funds
Gallery Leather Direct, Inc.
Joseph and Dorothy Goldberg
Charitable Trust
Golden Touch Imports, Inc.
Ingrid Vandebosch and Jeff Gordon
William Hard and Family
Alexandra A. Herzan
Homemakers Plaza, Inc.
Jane Hertzmark Hudis
International Cancer Research Partnership
International Flavors & Fragrances, Inc.
Jenny's Table
John Hardy
The Kay Family Foundation
Neil King
Lisa and Roger Krakoff
Mohan Kumar
LA Goes Pink
Friends and Family of
Grace Lambert-Carmichael
Denise LeFrak
Little Seed Farm
Liverpool Los Angeles
Liz Day Breast Cancer Research
Fit for a Cure, Friends and Family of
Lauren Loeb
MacroGenics, Inc.
Mara Hair and Mode Studio
Massachusetts General Hospital
Cancer Center
Nick Matuszewski
Musa Mayer
Family and Friends of Madeline McCloughan
McDermott Will & Emery
The Mehlman Family
Ronay and Richard Menschel
Merck Foundation
Meta
Misses Kisses
Morgan Stanley Pacific Coast Region
Andrea Newburger
Susan Newton
NewYork-Presbyterian Hospital
Nordstrom
North Family Fundraiser
NOVA Open Charitable Foundation, Inc.
Ocean Network Express
Ellen Odoner
Mary Alice Pappas

SUPPORT FROM COAST TO COAST

Patti's All-American
Pfaltzgraff
Pledge The Pink Foundation
Cynthia Hazen Polsky and Leon Polsky
Popular, Inc.
PowerHome Solar
Pretium Partners, LLC
Principle Choice Solutions
Jonathan Rackliffe
James Rauh
Rebecca's Foundation
Patty & Charles Ribakoff
Rolex Watch U.S.A., Inc.
Carolyn and Marc J. Rowan
Mitchell and Bonnie Rudin
The Late Rebecca Scheinkman and
Her Family and Friends
Sheryl and Barry K. Schwartz
Scrubs & Beyond
SCS Software
Smartpak Equine
Snap, Inc.
Spring Meadow Nursery, Inc./Proven
Winners® Color
St. Paul's Episcopal Church, Exton
Katherine Chapman Stemberg
Sting Soccer Club
Sudarsky Family Foundation
Phillip M. Tate
The Henry and Marilyn Taub Foundation
Rupert C. Thompson Fund
TikTok
Trina Turk
Uniforms Direct, Inc.
Up Down Cigar
UrbanStems Inc.
Kerone Vatel
VGW Holdings Limited
Robert Vogt
Iris M. Walker
Vera Wang
Drs. Tania Lingos and Andrew Webb
Renata Weiss
Lise and Jeffrey Wilks
Yale Cancer Center, Smilow Cancer Hospital

\$10,000 - \$14,999

Airo Brands, Inc.
Anne Klein
Aosom
ARL, Inc.
Artisan 34
Sharon and Ron Aylor
Balyasny Asset Management
Bandier Corp.
John and Myrna Barton
Marian D. Beerstecher

Bill Belichick and Linda Holliday
Gary Benink
Gigi and Harry Benson, CBE
Stefany and Simon Bergson
Judy Roth Berkowitz
Michael and Marcela Berland
David Berman
Cathy S. Bernard
Steven W. Beyer
Myra and Charles Biblowitz
Bio X Cell
Jane Sudler Black
Magda and Edward Bleier/Dana Foundation
Bland Farms, LLC
Blue Ridge Homeowners Association, Inc.
Blumenstein Family Foundation
Roberta and Stanley Bogen
George Brandt
Barbara and Christopher Brody
Brookline Bank & Clarendon Private
Randy and Randi Buller
CALZEDONIA USA Inc.
Louise Camuto
Capital Region Classic
Debra and Kenneth Caplan
Carbon 38, Inc.
Card My Yard
Chan Luu, LLC
Brandon and Susie Chatham
Greta and Brian Choi
CJBS, LLC
The Colony Hotel Palm Beach
Connatix Native Exchange
Kathleen E. Cook
Core Staffing Services, Inc.
Crown Family Philanthropies
Dalstrong, Inc.
Kenneth Damask
Danskin
Darkzero Esports
Storebound/Dash
Dee Ocleppo
John D. Demsey
Valerie and Charles Diker
Mary and Terry Dillon
James and Judith K. Dimon Foundation
DIOR
EasyGo Drinkware, LLC
Anne and Joel Ehrenkranz
Kathy Elsesser
Fern and Edward Emmer
Empower Electric, LLC
Carol Ann Blinken Emquies Charitable Fund
Ernst & Young LLP
F45 Training
Emilia and J. Pepe Fanjul
Catherine and John Farahi

Fein Foundation
David and Amy Field
Find a Cure RX Card
Penelope Fireman
Fiscal Realities Economists
Cathy Franklin and Jeffrey Baker
Jean Frazier
Alice Gantcher
David Geffen Foundation
Bruce and Lori Gendelman
Genomic Health
Mr. and Mrs. Barry Gertz
Michael A. Gilmore
Gary Gitelson
Nancy Goodes/Goodes Family Foundation
Pennelope Goodfriend
Michael A. Gould
Graber Family Foundation
Edmund A. Grossman
Audrey and Martin D. Gruss
The Marc Haas Foundation/Sydney
and Stanley S. Shuman
Hair La Vie
Hanesbrands
Wendy Harmon
Brian and Sara Harris
Erin and Brook Hazelton
Heinz Family Foundation
Irwin A. Herman
Susan L. Herman
Hinkley Lighting
Ellen Horing
Gigi Howard
Friends and Family of Qing Huang
ili New York
Interactive Communications International, Inc.
Jennifer Miller Ltd.
Johnson Family of Restaurants®
Kay and Robert Johnstone
K2 Sports
Mitchell Kaneff
Kansas City Council Benefit
Harry and Jill Kargman
Iny & Joel Karp
Sheryl and Chip Kaye
Paqui and Brian Kelly
Kiss Products, Inc.
Jennifer Kobus
Kramer, Dillof, Livingston & Moore
William Lang
Aerin Lauder
Jane Lauder
The Chase and Kristi Lieser Family Fund of
Thrivent Charitable Impact & Investing™
Shane K. Livingston
Lokai
Judith and Larry Luckett

Madewell
Massaro Family and Friends
Material Good
Marigay McKee
Robert Menschel and Janet Wallach
The Ben Miller Foundation
Missouri Star Quilt Company
Melissa Monk
Pauline K. Morgan
MUD GIRL™
The Right Honorable Brian Mulroney and
Mrs. Mila Mulroney
Cynthia and Larry Murphy
Raymond Murphy
Daniel Murray
National Mah Jongg League Foundation, Inc.
NetJets®
Nucor Steel Indiana
Maria and Dennis O'Leary
Bianna and Peter Orszag
Mary and Jonathan Orszag
Linda and Jonathan Penn
Carl Peterson
Pharaoun Cocktail Rings
Carole and Thom Phiebig
Pink Maison
Dawn Porter
Quilts & Treasures, Inc.
Vickie Randazza
Rimini Street
Barbara Roberts
Robert Rodin
John I. Ross
Christina and John Rossi
Rothy's
Rue La La
Joan Safir
Chella Safra
Jonathan and Marlene Sakol
Sam Edelman
The Sandler Family
Roger Saunders
Audrey and Mark Schuster
Gregg Sciabica
Senreve
Family and Friends of Clara Sharp
Paula Shearman
Chris and Carrie Shumway
Edwin and Linda Siegel
David E. and Jacqueline S. Simon
Charitable Foundation
Skinspirit Essential
Kevin Smith
Solan De Cabras
Soulon Inc.
Denise and Jeff St. Mary
Friends and Family of Danielle Stadelmann

Ana Demel and Gary Stein
Stryker
Jennifer Ames Stuart
Summer Fridays
The Sunshine Foundation
Scott Swank
Martha R. Swanson
Edward Swyer
Teleflora LLC
Norma Kline Tiefel Foundation
The TJX Companies, Inc.
Top Turf Inc.
Trish McEvoy, Ltd.
Ruth and Nicholas Tsoulos
Friends and Family of Patricia Friedel Steele
Susan Unterberg
James E. Uff
Wachtell, Lipton, Rosen & Katz
Weil, Gotshal & Manges LLP
J. Weinstein Foundation, Inc.
Wheeler Winery
Widex USA, Inc.
Jill and Paul Yablon
Augusta Zimmerman

IN-KIND GIFTS VALUED AT \$2,500 OR MORE

AERIN
Bombas
Conair Corporation/Ronald Diamond
Delta Air Lines
The Estée Lauder Companies Inc.
Granite Telecommunications, LLC
Gretta Enterprises
Jeffrey Levinson
Kendra Scott Design, Inc.
Kramer Portraits
LAGOS
Lifetime
Long's Jewelers
Maison Ullens
Mario Avila Design
MAS by Morgan Shara
McDermott Will & Emery
NAKEDCASHMERE
The New York Times Company
Perkies
Pierre Louis Mascia
Quotable Cards
Rafanelli Events
Reunited Clothing, LLC
Society Limonata
Tiffany & Co.
Vhernier
Weil, Gotshal & Manges LLP
Winston Flowers

EVELYN H. LAUDER CATALYST CIRCLE

**Recognizing individuals who have made a
\$250,000+ legacy gift to BCRF**

Lorraine Adelsdorf-Nudd
Lawrence Frank Adorni
Estate of Barbara A. Amann
Daniel M. Annese and Ron L. Mize
Jack Paul Barker
Robert Auguste Bernard
Melissa Lynn Burciaga
Margaret Colleen Burdette
Estate of Ruth Cole
Carroll Dianne Davis
Jamie Delaney
Lenin Estrada-Osorio and Johanna
Aguirre-Correa
Frank Lewis Fenn
Christine A. Ferer
Estate of Gregory Fleeman
Helen Elizabeth Fogle
Jean R. Furman
Julianne M. Furman
Russel Joseph Galjour
Anna Gilhooly
Arlene and Edmund Grossman
Elizabeth M. Gunn-Kidman
Karen R. Hale
Sherry Hawkes
Harriette Hersch Family Trust
Donald Higgins
Thomas Charles Hoffer
Jane Hertzmark Hudis
Georgia Marie Jennings
Paul Thomas Kennedy, Sr.
Shelly Kivell
Kay Krill
Deborah Krulewitch
Elyse Lacher
Estate of Susan Lamont
Sarah Joyce Lanyon
Evelyn H. Lauder CLAT
Melissa Anne Liberty
Lee Dove Lockie
Sonja Anne Loss
Barry E. Mayes
Michael Frederick Melchiondo
Edna U. Menke
Estate of Burton C. Meyer
Barbara A. Milos
Estate of William S. Molloy, Jr.
Jacqueline Neglia
Russell H. Norberg Trust
Lori A. Nunziato
Janet O'Connor
Heather and Andrew Olsen
Kirk Edward Pansing

SUPPORT FROM COAST TO COAST

Beth Park-Field Revocable Trust
Estate of Margaret Leigh Pate
Colleen Ann Peterson
Vickie Lynn Phillips
Peggy and Kevin Quinn
Francis Joseph Reiss
Robert T. Ridley
Gwendolyn Ruth Rominger
John Rosenwald
Gail and Charles Santorelli
Frances G. Scaife
Rebecca J. Schriver
Joseph R. Sebring
Brenda K. Smith
Marilyn W. Strickland
Anne and Mark Stumpf
Linda Swears
Rachel J. Trice
Estate of Robert and
Louise Trogden
Estate of Joyce Ann Trotta
Stanislav Uryasev
Suzanne B. Walchli
Cynthia C. Weiler and
E. Blake Moore, Jr.
Christine A. Will
Joan Wister CRUT
Brent Charles Yanagida

EVELYN H. LAUDER LEGACY SOCIETY

**Celebrating all individuals who
have chosen to make BCRF
part of their legacy***

Pedro Cesar Acosta
Heather Lynn Adams
Me'Lissa Yvonne Adams
Phillip Adsetts
The Augustine Agrizzo Trust
Martha Jane Chambers Akers
Bridget Marie Allen
Richard Craig and
Sandra Williams Allen
Stacie Renee Allen and
Gary Lee Allen
Sylvia Diane Almond
Judy Ann Alscheid
Isiah Alexandro Alvarez
Yadelin Amendola
Kristy Amoresano
Karen K. Anderegg
James Anderson and
Hannah Cash Anderson
Jonathan Garr Anderson
Darvin Jade Andrews
Mae Jovita G. Angelo
Mikayla Aragon

Andrea K. and
Nicholas K. Argires
Judith Guerra Arnold
Dorothy Arrieta Arrington
Joy Lavonne Ayers
Kathryn R. Bach
Henry and Lorraine Baez
Arthur William Ballantyne IV
Tyisha Nicole Bannerbie
Rita Agnes Barbari
Michael R. Barber
Audra Lynn Barclay
Beverly Grace Barnes and
William Armistead Hughes
Cassandra Marie Barnes
Anita Marie Barrett
Christina Anita Bascas
Alyssa C. Basdeo
Tomika Battle
Jennifer Irene Bearce
Shonda Denise Bell
Joseph Bentz
Eleanor Bergstein
Alan Eugene Bernstein
Jasmine Lee Berry
Carla L. Bethea
Dipasis Bhadra
Courtney M. Blackwell
Robert and Stephanie Blackwell
Lisa M. Blanchette
Brandon W. Blankenship
Magda and Edward Bleier
Jesse Ian and Amber Lynn Bliss
Linda Frances Bloom
Owen W. and Anne P. Blum
Becky Arlene Boros
Rhonda Lynn Boyd
Gladys Lucille Bracha
Rebecca Lyn Brackett and
Jason Bradley Brackett
Tanisha R. Braham
Estate of Gwyneth Branigan
Alexandrina C. Brannan
Susan Lynette Brewer
Carey Lester Brinson and
Kathleen M. Brinson
Lori S. Brizendine
Estate of Adele Brown
Elizabeth Ann Brown
Estate of Ethel M. Brown
Jeanne Ann Brown
Pansy Viola Browne
Donna M. Brun
William Cecil Brunson and
Anne Elizabeth Brunson
Jesseca Tamarey Brush
Lewis Thomas Bryant

Tyler Clay Bueford
Estate Of Vita Bulika
Gary A. Bultema
Estate of Nelda Burke
Estate of Patricia A. Burke
Janet Eileen Burkhart
James Jessie Burley
Kimberley Burlin Trust
Rebecca Michele Burns and
Ryan Michael Burns
Tamara Lynn Burton
Robert Joseph Businsky, Sr.
Beverly Patricia and
Neville Arthur Butcher
Dawna Lisa Butterfield
James Richard Caesar
Diane J. Cahn
Mr. and Mrs. Walter Cain
Angela Cain-Thompson
Brandy C. Callison
Brenna Mae Calnan
Jessica Lynn Campanaro
John D. Campbell
Aimee Suzanne Carlson
Sharon Wray Caron
Kimberly Ann Carroll-St. John
Matthew Ryan Carter
Richard Andrew Cary
Castiglione Charitable Trust
Lorenzo Josue Castillo
John H. & Dorothy M. Castle
Rashayne Catnott
Shannon Colleen Cavness
Kemba K. Chambers
Lauren Chase
Dan Chen
Irene Chepleting
Ashley Bryanne Chlarson-
Martinez
Barbara Jean and
Louie Cimmarusti
Jeremiah Matthew Cirino
Mark Alan Civick, Jr.
Frederick Dolland Clark
Brooks Aaron Coan
Thomas Cocuzza
Jacqueline Annette Cole
Mary Amanda Cole
Kristal Oglesby Coleman
Derek A. Colligan
Kala Marie Conley
Jacob Wayne Connors
Estate of Charlotte Kay Consales
Christine Consales
Singleton E. Conyers
Estate of Theodore M. Corbo
Tenika M. Cottingham

Della Louise Cowan
Elaine and Bobby Cowley
Connie Craden
Clark V. Craig
Deborah L. Crawford
Estate of Karen J. Crouch
Brittney Brianna Crump
Estate of Novella Cummings
Kortney Lynn Cunningham
Helen Davis
Deborah Ruth Davis
Elizabeth Renee Davis
Glenn Keith Davis
Katherine and Ronald Davis
Cheryl Dawn De Los Santos
The de Rothschild
Philanthropic Trust
Linda Deaton
Estate of Helen DeGennaro
Tricia Lynne Dejaynes
Kelly Lynn Delizza and
David Anthony Delizza
Baron and Melissa Desmond
Nathaniel Isaiah Deuel
Estate of Carol Dietrich
Estate of Thalia Diktaban
Donald Joseph Dilego
Christa Michelle Doak
Nicolette Gelina Dobbe
Shirley Frances Dobson
Destiny Leann Doherty
Amanda Lynn Dolinger
Chanel M. Douglas
Aric Drott
Pearl Elaine Dungey
Ruth A. Dungey
Tammy Marie Durbin
Estate of Rebecca J. Dyer
Anita Marie Eberts
Claire M. Edghill
Elizabeth A. Edmondson
Alexa Elaine Eisenbrown
Richard Lee and
Shareen L. Eissler
Philip W. Elgin
Frances Obianuju Emembolu
and Edmund Okocha
Estate of Miriam S. Enders
Estate of Mary Elizabeth English
Elizabeth Rose Erman
Betty Jean Ervin
Kimberly Elisabeth Eurich
Justin Dewayne Evans
Estate of Isabel Ewing
Amanda Beatrice Falk
Marcia Feldman Revocable Trust
Ronald J. Fell

Joseph A. Fella Living Trust
Rachel Marie Ferons
The Joan Ferrara Irrevocable Trust
Jessica Karina Figueroa
Britanee Anne Fillmer
Gavin Jackson Fleming
Deborah A. Cain Fletcher
Megan Flores
Amber Renee Floyd
Earline Foiles/John &
Kerry Rietmann Farms
Rachelle A. Fong
Audra Elaine Ford
Cynthia Marie Fortner
Rebecca Mackenzie Wyant
Foster
Cindy Miki Fountain
Sheri Mae Francis
Darryl Frazier
Chad Glenn Freeman
Tia Juanita Frye
Sallie Funderburk
Carrie A. Gallagher
Helen Galland-Loewus
Lorraine E. Galle
Mary Ann Gann
Annette A. Garcia and
Robert William Garcia
Gill Wayne Gaston
Vicky Louise Gatlin
Brianna Gauntlett and Tyler
James Brunais
Leslie Gerolde
Dona M. Giordano
Marlene Rosetta Glashen
Jodi Marie Glusco
John E. Goerlich
Jane Golub
Bertha Barbara Gonzalez-Corum
Audrey Lea and Billy Gooch
Michael D. Gooding
Jonathan Lennox Goodman
Darlena Goodwin
Kathleen R. Goodwin
Mona Gordon
Trecia Kay Gordon
Robert L. Gordon
Tracy Lynette Grant
Angela T. Grasso
Adria Nicole Gray
Damaris Patrice Green
Theodore Clark Greenlee
Barbara Griffin
Angela W. Groover
Satya P. Gupta
Dolores J. Guse
Jesse Gwozdz

C. J. Haardt
Shirley J. Hagens
James O. Halley
Frances Halper
Jan Perry and Christian Ham
Melva J. Hancock
Pauline Sue Handy
Lisa Medrano Harbert
Patricia Ann Harbour
Pamela Hard
David Edward Hardin
Monica L. Harrer
Melissa A. Harris and
Gregory Scott Harris
Tashya Marie Harris
Willow Madelyn Harris
Briana A. Haughton
Brandon J. Hawke
Maya Rae Hawkins-Nelson
Bailey L. Hayes
Christine Haynes
Beverly Sue and John Lewis Hays
Briana Elizabeth Hearndon
Rosanna Doughten Heffron
Casey Elizabeth Helmicki
Christopher G. Helton
Eugene L. Henricksen Trust
Joel Ira Hershey
Tanesa M. Hicks
Judith Anne Higginbotham
Dana Drew Hill
Shantel P. Hill-El
Aletia Maria Hodge
Linda J. Hokanson
Ryan P. Holder
Estate of Betty Holland
Tonya Michelle Homan
Jennifer Marie Hoover
Leslie Dawn Horton
Tammy F. Hoskins
Julie Ann Hovland
Denise Diane Howard
The Marilyn E. Howerton Trust
Debra A. Howlett
Katie Hull
Madelyn Rose Hungerford
Gayle Croft Husselbee
Nicki L. Isaacson
Oluwatosin O. Iyasele
David Eugenio Izquierdo and
Angela Vega
Trudy Jean Jacobs
Carole Jacqueline
Eliot Mitchell Jarrett
Lorena Jimenez
Maria Cristina Joachims
Mike Joachin

James Oscar Johnson
Annette Madeleine Johnson
Jo Lynne and David Johnson
Donna L. Johnson
Dorothy Elizabeth Johnson
Steven Jay Johnson
Treaa Johnson
Kymberly P. Jones
Christine M. Joyce Living Trust
Paula Jean Keller
Justin Lee Kelley
Joshua Lewis Kelly
Detra Shirley Kemmerer
Joseph Patrick Kennebeck
Dale E. Kern
Joseph M. Klauss
Sherri G. Kleen
Helene Susan Klotzkin
Mckenzie Rae Koschene
Leone Maria and
Paul Anand Kowlessar
Thomas Julian Krane
Meghan R. Kreger
Jennifer Ann Kruk
Margaret Aldona Kudirka
Patricia Kuhn
Nanthini Kumararajan
Bela and Erna Kurucz
The Patricia E. Laca Trust
Marguerite Lacy
Kevin Lee Lannon
Monica Holmes Lawson
Deborah Elaine Lazich
Claire T. Lecas
Jonathan N. Lehto
Wayne Leizear
Shelly J. Lemons
Jonita C. Leroy
Gerhardt Lesser
Virginia Green Liner
Estate of Harriet G. Lipsky
Estate of Thomas Elliott Little
Alexis Corey Littrell
Anthony Shane Lockridge
Haley Harwood Lockridge
Pamela and Joseph Charles
Lovell, Jr.
Estate of Felix Luczak
Joseph and Carol Maas
Katrina Roshan Mackey
Jenny Rebecca Macleod
Ryan C. Madden and
Emily Ann Madden
Michael and Rosemary Madigan
James P. Maestas
Jacqueline B. Magee
Roshanak Malek

Amirose Chang Mallet
Tracey Elizabeth Mangold
Elena Laura Mardesich
Michael David Margolis
Chantel Dominique Mark
Tyler Leeann Mars
Dr. Susan Marshall
Donald Martineau, Sr.
Memorial Fund
Victoria Lynn Mason
Zolani Loyiso Chukwuemeka
Bantu Matebese
Billie Dawn Matson
Mona Matthews Gordon
Trust and Estate
Robert Calvin Matthews
Estate of Judith Ann Maxon
Julie Kathryn May
Nicole Leann Mazurek
Hannah Elizabeth McCallister
Lauren A. McCauley
Bruce Edward Mccray
Melissa N. McCullough
Colin Daugherty Mcdowell
Marsha Ann Mcfarland
Shemika Murriel McGowan
Lebrey Lechell McKinney
Raxzuanne A. Mcleod
Donahoo McMenamy
Alicia Lorraine Mcmillian
Maryellen Mcname-Bailly
Nikky Lynn McNeil
Estate of Evelyn Meisner
Melissa Ann Merrell &
Thomas William Burgess III
Estate of Gene W. Metz
Morgan M. Metzger
Biakai Catharine Meye
Estate of Marilyn C. Miller
Jane-Ellen Miller
Stephanie Kretzmer Miller
Scott A. Miner
James C. Minery
Cheryl Louise Mings
Deborah Ann Minkel
Carolyn Misumi
Jodi Mae Mock
Janet E. Montgomery and
Gloria C. Montgomery
Estate of Mary Monti
Denise Maria Moody
Estate of Ann Mooney Asby
Roberta Faye Moore
Sally Hamilton Moos
Halle Cecelia Morgan
Estate of Rose L. and
Morris Kraft

Katherine D. Morrison
Alice A. Morro
Estate of Herman Douglas
Morrow
Robin Moshonov Revocable
Trust
Brian James Mosley
Cynthia E. Mouzon
Pamela A. Muia
Shannon Celeste Mulkey
Rachel Anne Mulliger
Eiko Murata
The Sylvia Nachsin Trust
Kimberly Michelle Nadal
Hugh M. Neil 2018
Revocable Trust
Daniela Neshovska
Kenneth Wharton Nichols
Brooke Leigh Norman
Taylor Nichole Oakes
Mary O'Connor
Dalton Shane Odom
Estate of Marga Oligney
Kennedy Alexis O'Malley-Dertien
Jan Opalach
Logan John Opie
Evelyn M. Ortiz
Louise Orzechowski
Mary Alice Pappas
Estate of Maxie Parker
Estate of Dorothy Parsons
Rogan Stanley Patterson
Estate of Frances Paulsen
Roshna Alex Pereira
Lawrence A. Pettke
Carol Phillips Beirne
Lois A. Pierce
Mark M. Pine
Steven C. Pipitone
Thomas Pitoscia
Eloine Planas Cordero
Beatrice Georgia Pohl
Ethan Trey Posey
Trisha Melia Powers
Sydney Marie Pressley
Beverly Leighann Price
Jessica Leighann Pryor
Dorothy A. Quinn
Riffat Imran Qureshi
Mallikarjun Rachamalla
Kimberly Anne Ragan
Alexis Rangel
Robin Jeannetta Raschard
Mahabeer
Alice Ravichandar
Timothy Gerard Redding
Helen D. Reed Family Trust

Rodney J. Reese
Eric K. Reich
Alexander F. Remington
Richard and Ann Reschly
Tom Reschly
Caroline Mae Reynolds
Stephanie Anne Rhoades
Shelby Marie Rhoads
Colin J. Rhodehamel
Yolanda Natasha Richards
Tyriq Lamont Riddick
Ann Elizabeth Riedl
Estate of Arthur M. Rigg
Bayla Krone Riggs Wynot
Christina Antoinette Rios
Cynthia Rios
Ricardo Jesus Rivera and
Maria Esther Camacho
Carianne Rodriguez and
Christina Lynn Archer
Mayala Rodriguez
Andrea Carmela Roposh
Maria Rowland
Christine Anne Rudy-Reed
Suzanne Lyn Rudy-Reed
Dominic J. Ruschetta Trust
Christina Salguero
Craig Joseph Saliba
Pamela J. Samples
Mary Field Sanford Trust
Valeria Hassel Sanchez
Nora E. Santa Cruz
Laura M. Savinon
Leah K. Saxion
Audrey and David Schechter
Estate of Robert A. Schmid
Nicole L. Schoof
Ann Corinne Scott and
Gary Lee Scott
Michelle Lynn Scott
Audrey Secular
Timothy D. Seeley
Lisa Shapiro
Meryl Lyn Shapiro
Nanci Lynne Shaw
Jianhui Shen
Alan H. Shepherd Trust
Michele Elaine Showkeir
Sarah Jean Shuler
Laura E. Shumac
Michelle Anne Shumaker
Julien Giulio Sidoli
Estate of Robert P. Siegel
Jeannine Bouillier Siegmond
Ann Lynne Silverman
Katie Elizabeth Slone
Ford M. Smith

Michael Tyrenn Smith
Roberta A. Smith
Martha M. Sohn
Blythe Ann Sparks
Jeffery Wayne Speaks
Doris Speisman
Genevieve Evadne Spence
John K. Spraggins
Yvonne Marie Spruill
Laterrica Dainne and
William Cortaina Stegall
Nancy Stevenson
Lori Stober
Jacob Andrew Stokes
Cody James Stone
Cathy L. Stouder
Michael Richard Stubblefield
Estate Of Rochelle Sturza
Martisha Ann Summers
Mindy Swanson
Kristin Rebekah Sweeney
Courtney Marie Symons
Miguel Angel Tactuk
Paula Marie Tamburri
Abigail Noel Taylor
Angela B. Taylor
Steel Clarizen Taylor
Stephanie Lashonda Taylor
Carla Rene Teitelbaum
Anthony P. and Carol Teri
Samara J. Thomas
Michael Allen Thompson
Scott Hamilton Thompson
Susan Celestine Thompson
Laura Ann Thompson-Hotinger
Jacquelyn S. Thornton
Sharon Ann Tomlin-Battle
Adriana Toribio
Giuliana Milagros Torres
Leslie Jeanne Tortorelli
Mang Duoc Dinh Tran
Jaclyn Abby Truesdell
Elizabeth T. Tsai
Cheryl M. Tucker
Sheri Laree Tully
Tuma Family Trust
Wassil Tussov
Estate of Betty Ann Utterback
Rosa Esther Valdez
Khrysta L. Vandenburgh
Ada A. Vazquez
Gina Geovanna Encalada Vera
Cristina Lynn Via
Maria De La Luz Villalobos
Everett A. Walden
Estate of Emily A. Walker
Frederico Antonio Gibran Walker

Jeffrey Lamont Wallace
Henry N. Walters
Clay Daniel Wanta
Gwendolyn Felicia Ward
Ward K. Warner Revocable Trust
Stephen Henry Washington, Jr.
Marci Anne Waterman
Maria Jose Watson
Wynell Angela Watson
Lisa Gale Weeks and Terry Weeks
Lesma Dorothy Weir
Vicki Weiss Trust
Nicol Teresa Wells
Margaret Donnell and
William White
Cheri A. White-Paredes
Joyce E. Whitted
Sara Elizabeth Whittington
Donald Wilkerson, Jr.
Charlene L. Williams
Lamorna Spears Williams
Wendy A. Williams
Jada Rylan Wills
Jackye Lynn Wilson
Marion Louestera Wilson
Donna Jeanne Winfrey
Wilbur and Delores L. Woo
Jennifer Sue Wood
James Mark Worlin
Merritt Todd Wright and
Suzy Richards Wright
Weifeng Yang
George Allan Zadanski
Kenneth J. Zambello
Suzanne B. Zea
Misty Lee Ann Zumwalt
Lois K. Zussman
Milton Y. Zussman

*Recognizing bequest commitments over \$500, and FreeWill commitments over \$5,000 made prior to Fiscal Year 2022. BCRF remains deeply grateful for commitments at all levels.

The Breast Cancer Research Foundation's 2022 Major Donor List includes gifts received by the Foundation between July 1, 2021 through June 30, 2022. Every effort has been made to guarantee the accuracy of this list. Please contact us at 646-497-2680 or bcrf@bcrf.org if we have omitted your name or you wish to be listed differently in the future. Thank you for your support.



2022-2023 GRANTEES

UNITED STATES OF AMERICA

ARIZONA

Arizona State University Foundation for a New American University
Joshua LaBaer, MD, PhD
The Play for P.I.N.K. Award

CALIFORNIA

Ellison Institute Research Foundation
David B. Agus, MD
The AutoNation DRV PNK Award

Salk Institute for Biological Studies
Geoffrey M. Wahl, PhD
The Play for P.I.N.K. Award

Stanford University
Michael F. Clarke, MD

Christina Curtis, PhD, MS, MSc
The Ulta Beauty Award

James Ford, MD
The Joseph and Arlene Taub Foundation Award

Allison Kurian, MD

Mark Pegram, MD

Robert West, MD, PhD

University of California, Berkeley
Adam Yala, PhD
The AI Screening Project supported by Zeta Tau Alpha Foundation

University of California, Los Angeles
Julienne Bower, PhD
The Estée Lauder Companies' Breast Cancer Campaign Award

Steven W. Cole, PhD
The Estée Lauder Companies' Breast Cancer Campaign Award

Patricia A. Ganz, MD
The Estée Lauder Award

Annette L. Stanton, PhD

University of California, San Francisco
Alan Ashworth, PhD, FRSC

Laura Esserman, MD, MBA

Scarlett Gomez, PhD, MPH
The Estée Lauder Companies' Travel Retail Award

Hope Rugo, MD
The Ulta Beauty Award

Laura van't Veer, PhD

Valerie Weaver, PhD

University of Southern California
James Hicks, PhD
The Women's Cancer Research Fund Award

Peter Kuhn, PhD
The Women's Cancer Research Fund Award

Michael F. Press, MD, PhD

COLORADO

University of Colorado, Denver
Kathryn Horwitz, PhD

Carol Sartorius, PhD

CONNECTICUT

Yale School of Medicine
Kim Blenman, PhD
American Association of Cancer Research

Mehra Golshan, MD, MBA
The Hale Family Award

Ian Krop, MD

Lajos Pusztai, MD, DPhil

David Rimm, MD, PhD

Eric Winer, MD

The Play for P.I.N.K. Aquidneck Club Award

Yale School of Public Health
Melinda Irwin, PhD, MPH
The Westchester Women's Award in Memory of Marla Mehlman

DISTRICT OF COLUMBIA

Georgetown University
Marc Lippman, MD

Joyce Slingerland, MD, PhD

Sandra Swain, MD

FLORIDA

H. Lee Moffitt Cancer Center & Research Institute
Kimberley Lee, MD, MHS
The AutoNation DRV PNK Award in Memory of Jason Jenkins
American Association of Cancer Research

Mayo Clinic Comprehensive Cancer Center Jacksonville, FL
E. Aubrey Thompson, PhD
The Play for P.I.N.K. Delaire Country Club Award

GEORGIA

Georgia Institute of Technology
Stanislav Emelianov, PhD
The Delta Air Lines Award

Emory University
Kevin Kalinsky, MD
The Cure in Our Lifetime Award

Mylin A. Torres, MD
Conquer Cancer, the ASCO Foundation

2022-2023 GRANTEES

ILLINOIS

Alliance for Clinical Trials in Oncology
Suzanne George, MD

Loyola University Chicago
Kathy S. Albain, MD, FACP, FASCO
The Ulta Beauty Award

Clodia Osipo, PhD
The Ulta Beauty Award

Northwestern University
William Gradishar, MD, FACP

Seema Khan, MD

The University of Chicago
Frederick Howard, MD
Conquer Cancer, the ASCO Foundation

Dezheng Huo, PhD
The Ulta Beauty Award

Rita Nanda, MD

Olufunmilayo I. Olopade, MD, FACP
*The Estée Lauder Companies' Brands Award
in Memory of Evelyn H. Lauder
The Ulta Beauty Award*

University of Illinois, Urbana-Champaign
Benita S. Katzenellenbogen, PhD
The Play for P.I.N.K. Award

John A. Katzenellenbogen, PhD

INDIANA

Indiana University School of Medicine
Kathy D. Miller, MD

KANSAS

University of Kansas Medical Center
Carol J. Fabian, MD

Priyanka Sharma, MD

MARYLAND

Johns Hopkins University Bloomberg School
of Public Health
Kala Visvanathan, MBBS, FRACP, MHS

Johns Hopkins University School of Medicine
Rohini Bhatia, MD
American Society for Radiation Oncology

Andrew Ewald, PhD
The Play for P.I.N.K. Award

Elizabeth M. Jaffee, MD, FAACP, FACP
The Clinique Award

Andrea Richardson, MD, PhD

Dipali Sharma, PhD
The Macy's Award

Vered Stearns, MD
The Estée Lauder Award

Antonio Wolff, MD
*Translational Breast Cancer
Research Consortium*

MASSACHUSETTS

Beth Israel Deaconess Medical Center
Nadine Tung, MD
The Joan Lunden Award

Gerburg Wulf, MD, PhD

Boston Children's Hospital
Marsha A. Moses, PhD
The Hale Family Award

Zoltan Szallasi, MD
The Hale Family Award

Boston University School of Medicine
Dennis Jones, PhD
American Association of Cancer Research

Dana-Farber/Brigham and Women's
Cancer Center
Stuart Schnitt, MD
The Joan Lunden Award

Dana-Farber Cancer Institute
Myles Brown, MD
*The Pink Promises Award in Memory of
Bonnie Karp Schwartz*

Lewis Cantley, PhD

Alan D'Andrea, MD
The Clinique Award

Tamidayo Fadelu, MD, MPH
Conquer Cancer, the ASCO Foundation

Judy E. Garber, MD, MPH
The Hale Family Award

Sheheryar Kabraji, BMBCh
American Association of Cancer Research

William Kaelin, MD
The Ulta Beauty Award

Panagiotis Konstantinopoulos, MD, PhD
*The Play for P.I.N.K. Award in Honor of
Laura Lassman and in Memory of Nicholas
Lassman*

José Pablo Leone, MD

Nancy U. Lin, MD
*The Friends and Family of Jen and Josh
Feinberg Award*

Ursula A. Matulonis, MD
*The Play for P.I.N.K. Award in Honor of
Laura Lassman and in Memory of Nicholas
Lassman*

Elizabeth Mittendorf, MD, PhD
*The Hale Family Award
Cancer Research Institute*

Ann Partridge, MD, MPH
The Pink Agenda Award

Kornelia Polyak, MD, PhD
The Ulta Beauty Award

Nikhil Wagle, MD
*The Estée Lauder Companies' Employee
Fundraising Award*

Adrienne Waks, MD
Conquer Cancer, the ASCO Foundation

Jean Zhao, PhD

Harvard Medical School
Joan S. Brugge, PhD
The Play for P.I.N.K. Award

Harvard T.H. Chan School of Public Health
Walter C. Willett, MD, DrPH
The Hale Family Award

Massachusetts General Hospital
Priscilla K. Brastianos, MD
*The Boston Hot Pink Luncheon Award in
Honor of Nancy and Rick Kelleher*

Daniel A. Haber, MD, PhD
The Howard and Michele Kessler Award

Rachel Jimenez, MD
Conquer Cancer, the ASCO Foundation

Constance Lehman, MD, PhD
The Lampert Foundation Award

Shyamala Maheswaran, PhD

Dennis Sgroi, MD

Neelima Vidula, MD
*The Housewares Charity Foundation Award
Conquer Cancer, the ASCO Foundation*

Massachusetts Institute of Technology
Regina Barzilay, PhD
*The AI Screening Project supported by
Zeta Tau Alpha Foundation*

Tufts University School of Medicine
Charlotte Kuperwasser, PhD

Whitehead Institute for Biomedical Research
Robert A. Weinberg, PhD
The Hale Family Award

MICHIGAN

Michigan State University
Karen Liby, PhD

University of Michigan
Sofia D. Merajver, MD, PhD
The Delta Air Lines Award

Lori J. Pierce, MD, FASCO, FASTRO
The Ulta Beauty Award

James M. Rae, PhD
The Macy's Award

Shaomeng Wang, PhD

Stephen J. Weiss, MD
The Play for P.I.N.K. Award

Max S. Wicha, MD

MINNESOTA

Mayo Clinic Cancer Center
Rochester, MN

Fergus Couch, PhD
The Ulta Beauty Award

James Ingle, MD
The Delta Air Lines Award

Charles Loprinzi, MD

Liewei Wang, MD, PhD
The Delta Air Lines Award

MISSOURI

Washington University in St. Louis
Graham A. Colditz, MD, DrPH, MPH
The Macy's Award

Farrokh Dehdahsti, MD

Cynthia X. Ma, MD, PhD

NEW JERSEY

Hackensack University Medical Center
Rena Feinman, MSc, PhD

Princeton University
Yibin Kang, PhD

Rutgers University Cancer Institute of
New Jersey
Bruce Haffty, MD
The Tatiana and Peter Cancro Award

NEW YORK

Albert Einstein College of Medicine
Rachel Hazan, PhD
The Neil and Jane Golub Award

Hayley McDaid, PhD
The David Yurman Award

Thomas E. Rohan, MBBS, PhD, DHSc

Cold Spring Harbor Laboratory
Jeremy Borniger, PhD
American Association for Cancer Research

Michael Wigler, PhD

Columbia University Irving Medical Center
Dawn L. Hershman, MD, MS
The Pink Agenda Award

Sandra Ryeom, PhD
*The Garrett B. Smith Foundation/S. Arthur
and Dorothy Neufeld Foundation Award*

Columbia University Mailman School of
Public Health
Regina M. Santella, PhD
The Aveda Award

Mary Beth Terry, PhD
The Aveda Award

Hunter College/City University of New York
Jill Bargonetti, PhD
*The Estée Lauder Companies' Brands Award
in Memory of Evelyn H. Lauder*

Icahn School of Medicine at Mount Sinai
Hanna Irie, MD, PhD
The Amy Robach Award

Elisa Port, MD, FACS
The Amy Robach Award

Joseph A. Sparano, MD
The Myra J. Biblowit Award
The Ulta Beauty Award
Coalition of Cancer Cooperative Groups
Eastern Cooperative Oncology Group

Memorial Sloan Kettering Cancer Center
Robert Benezra, PhD
*The Play for P.I.N.K. Award in memory of
Doris L. Mortman*

Sarat Chandralapaty, MD, PhD
The David Yurman Award

Elizabeth Comen, MD
The Lampert Foundation Award

Christopher E. Comstock, MD

Joseph O. Deasy, PhD
The Simons Foundation Award

Hedvig Hricak, MD, PhD
The Lifetime Award

Neil Iyengar, MD
The Pink Agenda Award

Maria Jasin, PhD, FACR
*The Estée Lauder Companies' North
American Research & Development and
Manufacturing Award*

Larry Norton, MD, FASCO, FAACR
The Neil and Jane Golub Award
The Simons Foundation Award

Kenneth Offit, MD MPH
*The Gray Foundation and BCRF
Collaborative Award*

Simon N. Powell, MD, PhD

Jorge Reis-Filho, MD, PhD, FRCPath
*The Estée Lauder Companies' North
American Research & Development and
Manufacturing Award*

Mark Robson, MD
The Taub Family Award

Neal Rosen, MD, PhD
*The Joseph and Arlene Taub Foundation
Award*

Tiffany Traina, MD

NYU School of Medicine
Juhi Purswani, MD
American Society of Radiation Oncology

Robert J. Schneider, PhD

Roswell Park Cancer Institute
Christine B. Ambrosone, PhD
The Play for P.I.N.K. Award

Chi-Chen Hong, PhD
The Play for P.I.N.K. Award

The Rockefeller University
Titia de Lange, PhD
The Macy's Award

Sir Paul Nurse, PhD, FRS
*The Sir Elton John Award Endowed by
Leonard A. Lauder*

Michael O'Donnell, PhD

Sohail Tavazoie, MD, PhD
The Lampert Foundation Award

State University of New York at Stony Brook
Allen Tannenbaum, PhD
The Simons Foundation Award

Weill Cornell Medical College
Melissa Davis, PhD

Sandra Demaria, MD
The Ulta Beauty Award

Silvia Formenti, MD
The Ulta Beauty Award

William Holloman, PhD

Tan A. Ince, MD, PhD

Taha Merghoub, PhD
The Play for P.I.N.K. Millbrook Award

Lisa Newman, MD, MPH
The Genentech Award

Jedd Wolchok, MD, PhD, FASCO
The Play for P.I.N.K. Millbrook Award

NORTH CAROLINA

Duke University
Alice Y. Ho, MD, MBA

Shelley Hwang, MD, MPH
The Tanger Factory Outlets Award

University of North Carolina, Chapel Hill
Lisa A. Carey, MD, ScM, FASCO
*The Pink Promises Award in Memory
of Sue Decina*

Marjory Charlot, MD, MPH, MSc
*The Estée Lauder Companies' Beauty Perks
North America Online Award*
Conquer Cancer, the ASCO Foundation

H. Shelton Earp, MD
The Estée Lauder Award

Stephen D. Hursting, PhD, MPH

Joannie Ivory, MSPH, MD
Conquer Cancer, the ASCO Foundation

Hyman B. Muss, MD
The Play for P.I.N.K. Award

2022-2023 GRANTEES

Charles M. Perou, PhD
The Susan Hertog Award

OHIO

Cleveland Clinic
Charis Eng, MD, PhD, FACP
The von Mandl Family Foundation Award

The Ohio State University
Samilia Obeng-Gyasi, MPH, MD
Conquer Cancer, the ASCO Foundation

Electra Paskett, PhD, MSPH
The Play for P.I.N.K. Award

Dionisia Quiroga, DO, PhD
The Hirschhorn Award in Honor of Susan B. Hirschhorn and in Memory of her mother, Ellen S. Hirschhorn
Conquer Cancer, the ASCO Foundation

OREGON

Oregon Health and Science University
Gordon Mills, MD, PhD

Joshua Saldivar, PhD
American Association for Cancer Research

PENNSYLVANIA

University of Pennsylvania, Perelman School of Medicine

Lewis A. Chodosh, MD, PhD
The William P. Lauder Award

Angela DeMichele, MD, MSCE

Susan M. Domchek, MD
The Pink Agenda Award

Mark I. Greene, MD, PhD, FRCP

Andy Minn, MD, PhD
The William P. Lauder Award

Katherine L. Nathanson, MD
The Ulta Beauty Award

Lawrence Shulman, MD, MACP, FASCO
The Estée Lauder Companies' Employee Fundraising Awards

Robert H. Vonderheide, MD, DPhil
The Leonard and Judy Lauder Fund Award

University of Pittsburgh Cancer Institute
Wendie Berg, MD, PhD, FACR, FSBI
The Lane Bryant Award

Adrian Lee, PhD

Steffi Oesterreich, PhD

Norman Wolmark, MD
National Surgical Adjuvant Breast and Bowel Project

TENNESSEE

University of Tennessee
Debra Barton, RN, PhD, FAAN

Vanderbilt University
David Cortez, PhD
The Ulta Beauty Award

Rodney Dorand, PhD, MD
Conquer Cancer, the ASCO Foundation

Ben Park, MD, PhD
The Ulta Beauty Award

Sonya Reid, MD, MPH
The Estée Lauder Companies' Charitable Foundation Award
Conquer Cancer, the ASCO Foundation

TEXAS

Baylor College of Medicine
Suzanne Fuqua, PhD
The Kendra Scott Award in Honor of Holley Rothell Kitchen

C. Kent Osborne, MD
The Macy's Award

Rachel Schiff, PhD
The Macy's Award

Xiang Zhang, PhD

Houston Methodist Research Institute
Jenny Chang, MD
The Estée Lauder Award

University of Texas MD Anderson Cancer Center
Michael Andreeff, MD, PhD
The AutoNation DRV PNK Award

Abenaa Brewster, MD
The Delta Air Lines Award

Powel H. Brown, MD, PhD
The AutoNation DRV PNK Award

Marianna Chavez Mac Gregor, MD, MSC
The Estée Lauder Companies' Employee Fundraising Award

Zhen Fan, MD

Chelain Goodman, MD, PhD
American Society for Radiation Oncology

W. Fraser Symmans, MB, ChB
The Ulta Beauty Award

Naoto Ueno, MD, PhD
The Clinique Award

University of Texas Southwestern Medical Center
Carlos L. Arteaga, MD
The Play for P.I.N.K. Award

Ariella Hanker, PhD

Heather McArthur, MD, MPH

UTAH

University of Utah
Alana Welm, PhD

WASHINGTON

Fred Hutchinson Cancer Research Center
Nancy E. Davidson, MD
The Estée Lauder Companies' Charitable Foundation Award

Thomas W. Kensler, PhD

Christopher Li, MD, PhD, MPH

Anne McTiernan, MD, PhD
The Play for P.I.N.K. Award

University of Washington
Mary Disis, MD
The Delta Air Lines Award

Mary-Claire King, PhD
The Roslyn and Leslie Goldstein Award

Hannah Linden, MD

WISCONSIN

University of Wisconsin, Madison
Vincent Cryns, MD

AUSTRALIA

Peter MacCallum Cancer Center
Prudence Francis, MBBS, B Med Sc, FRACP, MD
The Delta Air Lines Award

The Walter and Eliza Hall Institute of Medical Research
Geoffrey Lindeman, MBBS (Hons), FRACP, PhD

University of Melbourne
Sherene Loi, MBBS (Hons), FRACP, PhD, FAHMS
The Cynthia Lufkin Award

BELGIUM

Katholieke Universiteit
Christine Desmedt, PhD
European Organisation for Research and Treatment of Cancer (EORTC)

Institut Jules Bordet
Martine J. Piccart, MD, PhD
The Leonard and Judy Lauder Fund Award
Breast International Group (BIG)

Christos Sotiriou, MD, PhD

CANADA

BC Cancer, part of the Provincial Health Services Authority
Samuel Aparicio, PhD, FRCPath, FRSC
The Estée Lauder Companies' North American Research & Development and Manufacturing Award

Princess Margaret Cancer Centre
David Cescon, MD, PhD
*The von Mandl Family Foundation Award
Conquer Cancer, the ASCO Foundation*

University Health Network
Melinda Mushonga, MBChB, MMed
Conquer Cancer, the ASCO Foundation

University of Toronto/Mount Sinai Hospital
Pamela J. Goodwin, MD, MSc, FRCPC

FRANCE

Institut Curie/Hospital Rene Huguenin
Rosette Lidereau, PhD

Institut Gustave Roussy
Fabrice André, MD, PhD
*The Estée Lauder Companies' Brands Award
in Memory of Evelyn H. Lauder*

Mary Alice Franzoi, MD
Conquer Cancer, the ASCO Foundation

IRELAND

University College Cork - National University of
Ireland, Cork
Roisin Connolly, MD

ISRAEL

Clalit National Israeli Cancer Control Center
Gad Rennert, MD, PhD
The Delta Air Lines Award

Shaare Zedek Medical Center
Ephrat Levy-Lahad, MD
The Roslyn and Leslie Goldstein Award

ITALY

Fondazione Michelangelo ONLUS
Luca Gianni, MD
The Delta Air Lines Award

Hospital of Prato, Istituto Toscano Tumori
Laura Biganzoli, MD, PhD
*The Estée Lauder Companies' Employee
Fundraising Award*

PALESTINIAN AUTHORITY

Bethlehem University
Moien Kanaan, PhD
The Roslyn and Leslie Goldstein Award

RWANDA

Butaro Cancer Center
Cyprien Shyirambere, MMed
*The Estée Lauder Companies' Employee
Fundraising Award*

SPAIN

Fundació Clínic per a la Recerca Biomèdica
Aleix Prat, PhD, MD

Vall d'Hebron Institute of Oncology
Joaquín Arribas, PhD
The Ulta Beauty Award

Mafalda Oliveira, MD, PhD

SWITZERLAND

International Breast Cancer Study Group
Meredith M. Regan, ScD
Dana-Farber Cancer Institute

University of Lausanne
Johanna Joyce, PhD

UNITED KINGDOM

Brighton and Sussex Medical School
Dame Lesley Fallowfield, DPhil, DBE
*The Estée Lauder Companies' Brands Award
in Memory of Evelyn H. Lauder*

Institute of Cancer Research, UK
Andrew Tutt, MBChB
*The Estée Lauder Companies' UK & Ireland
Award in honor of Elizabeth Hurley*

Queen Mary University of London
Jack Cuzick, PhD, FRS, CBE
The Delta Air Lines Award

University of Cambridge
Serena Nik-Zainal, PhD

University College of London Cancer Institute/
Francis Crick Institute
**Charles Swanton, MBBS, PhD, FRCP,
FMedSci, FRS**

University of Oxford
Adrian Harris, MD, DPhil

FINANCIALS

BCRF is recognized as one of the nation's most fiscally responsible nonprofits. The Foundation continues to be the highest-rated breast cancer research organization in the U.S. and is currently the largest private funder of breast cancer research in the world.



STATEMENT OF ACTIVITIES FOR THE YEAR ENDED JUNE 30, 2022

PUBLIC SUPPORT AND REVENUE

PUBLIC SUPPORT:

Contributions	\$ 69,331,557
Special Events	14,143,316
Less: Direct benefit to donor costs	(1,442,152)
Total public support	\$ 82,032,721

REVENUE:

Grant Refunds	\$ 1,762,345
Net investment income/(loss)	(6,492,413)
Other income	1,005,356
Total revenue	\$ (3,724,712)
Total public support and revenue	\$ 78,308,009

EXPENSES:

Program Services	\$ 58,126,227
Management and General	3,946,203
Fundraising	8,659,568
Total expenses	\$ 70,731,998

Change in net assets	\$ 7,576,011
-----------------------------	---------------------

STATEMENT OF POSITION AS OF JUNE 30, 2022

ASSETS:

Cash	\$ 29,181,726
Investments	78,080,199
Pledges receivable	22,361,318
Prepaid expenses	62,641
Other receivables	237,220
Property and equipment, net	24,949
Security deposits	100,671
Total assets	\$ 130,048,724

LIABILITIES AND NET ASSETS:

Liabilities:

Accounts payable and accrued expenses	\$ 7,853,668
Grants payable	57,894,993
Total liabilities	\$ 65,748,661

Net assets:

Without Donor Restrictions	\$ 30,818,530
With Donor Restrictions for time and purpose	26,296,028
With Donor Restrictions, perpetual in nature	7,185,505
Total net assets	\$ 64,300,063
Total liabilities and net assets	\$ 130,048,724

JOIN THE EVELYN H. LAUDER LEGACY SOCIETY

By making a bequest to BCRF—a gift in your will or living trust that costs you nothing in your lifetime—you can ensure future funding for breast cancer research and continuing innovation.

Bequests are flexible and may be for a specific dollar amount, a percentage of your assets, specific assets, or what's left after making certain other dispositions of your assets.

To make the process of writing a will and creating a bequest easy, we've partnered with FreeWill to give you an online tool that allows you to write your will and arrange for a future gift to BCRF.

Visit FreeWill.com/BCRF to start your legacy today.

CONTACT US:

legacy@bcrf.org
646-497-2680

LEARN MORE:

bcrf.org/legacy



— CONSTANCE
DIAGNOSED IN 1999



THE BREAST CANCER RESEARCH FOUNDATION

28 W 44th Street, Suite 609, New York, NY 10036
646-497-2600
www.bcrf.org

  BCRFcure
 facebook.com/TheBreastCancerResearchFoundation
 twitter.com/bcrfcure